Navigation Links
Arizona companies team up, providing quick development of cancer drugs
Date:1/26/2011

FLAGSTAFF, Ariz. Jan. 26, 2011 TGen Drug Development (TD2) and Flagship Biosciences today announced a strategic alliance that should help speed new drugs safely into human testing and quickly benefit cancer patients.

TD2, based in Scottsdale, Ariz., provides drug development firms with expertise in moving promising laboratory discoveries through the pre-clinical, clinical and regulatory approval steps of getting new drugs to patients as quickly and safely as possible.

Flagship Biosciences, based in Flagstaff, Ariz., will greatly assist in this process by providing high-throughput, multiplexed immunohistochemistry expertise to support preclinical drug development and human clinical trials.

"Flagship's technology will significantly accelerate our ability to identify biomarkers that could help researchers predict which drug compounds will work best on specific patient cancers," said TD2 President Dr. Stephen Gately.

And because Flagship's affiliated laboratories are certified by the U.S. Food and Drug Administration, under the 1988 federal Clinical Laboratory Improvement Amendments (CLIA) law, these findings can be translated directly into clinical trials, where they can benefit patients as quickly as possible.

Specifically, Flagship provides computerized histopathology, the microscopic study of diseased tissue, which is a critical part of anatomical pathology and key to the accurate diagnosis of cancer and other diseases from sample tissues. Flagship also provides deep expertise in measuring epithelialmesenchymal transition (EMT), the process in which tumor cells become highly invasive, migratory and resistance to therapy.

"The local tumor environment is key to understanding efficacy and toxicity of oncology compounds in both preclinical and clinical trials, and EMT is central to understanding stromal involvement and fibrosis in cancer patients," said Dr. Gately. "Working with Flagship Biosciences brings a wealth of pathology knowledge in pharmaceutical product development, experience in difficult histology analysis."

When combined with TD2's integrated suite of molecular analysis tools designed to reduce the uncertainty in the drug development process, the partnership with Flagship will provide emerging drug companies with the promise of quickly and safely getting their discoveries to market.

"TD2 is the world-leader in novel approaches to oncology and oncology clinical trials," said Dr. David Young, President of Flagship Biosciences. "It is exciting to be partnering with TD2, and combining our quantitative pathology with TD2's oncology and molecular tumor profiling expertise. TD2's leadership in novel approaches to oncology clinical trials is an exciting match for digital pathology techniques and the promise of quantitative and virtual pathology analysis of patients and tumor response."

"This partnership is a further demonstration of the emerging regional strength of Arizona for biotech product development," said Dr. Robert Kellar, a board member of Flagship Biosciences. "Arizona is a unique resource for pharma, biotech, and device clients looking for the rapid application of new technology in development and clinical trials."


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related biology news :

1. Experts converge at Arizona State University for first preventive cancer vaccine conference
2. ASU professor named top in state of Arizona
3. NIH funds center at Arizona State to battle infectious diseases
4. University of Arizona-led group awarded $9.9 million to develop super rice
5. New research will unravel Arizonas prehistoric puzzle of the Hohokam ceramic industry
6. First Arizona Strides for Life event nets $25,000 for TGen research
7. TGen provides Arizona with $77 million in annual economic impact
8. DOE funds bio-inspired solar fuel center at Arizona State
9. Reportlinker Adds Biomarkers - technologies, markets and companies
10. TGen Drug Development accompanies GPEC to BayBio2010
11. Study highlights sustainable footprint of chemical companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based ... to 2022", published by MarketsandMarkets, the market is expected to be worth USD ... 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, has ... The bold new look is part of a transformation to increase awareness, appeal to ... period. , It will also expand its service offering from its signature gourmet cooking ...
(Date:10/10/2017)... 10, 2017 International research firm Parks Associates announced ... at the TMA 2017 Annual Meeting , October 11 in ... residential home security market and how smart safety and security products impact ... Parks Associates: Smart Home ... "The residential security market has ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
Breaking Biology Technology: